Analysis of the prevalence of gastrointestinal malignancies
DOI: 10.32364/2587-6821-2021-5-8-525-530
S.V. German, I.P. Bobrovnitskiy, A.V. Balakaeva
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russian Federation
Background: malignancies are a critical issue of healthcare worldwide and rank second among leading causes of death. Gastrointestinal (GI) cancer morbidity and mortality are different across national populations and even territories of one country. A set of factors affect GI cancer prevalence, e.g., social-economic, climatic geographical, ecological, behavioral, hereditary factors of the living environment, etc.
Aim: was to analyze the rate of GI cancers among habitants of northern regions of Russia and its changes over five years and compare these data to the Russian population.
Materials and Methods: official statistical data of the P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre (2016–2019) were used. In addition, published data on GI malignancies indexed in Medline, PubMed, Web of Science, Scopus, and Google Scholar databases were reviewed.
Results: a higher rate of GI cancers among populations of northern regions of Russia (more remarkable than in Russia) was reported. Standardized incidence varied from 4.84±0.63 in the Murmansk Region to 12.72±4.64 in the Chukotka autonomous region. The exclusions were the Krasnoyarsk region and Khanty-Mansy autonomous region. In these regions, the incidence was similar to all-Russian incidence. In men, GI malignancies develop several years earlier than in women, i.e., the difference varies between 1.5 years (colon cancer) and 5.6 years (pancreatic cancer). The leading malignancies in Russia are gastric cancer and colon cancer.
Conclusion: cancer prevalence and risk factors in populations of northern regions of Russia provide novel modalities to improve preventive and treatment strategies for malignancies.
Keywords: malignancies, digestive organs, Helicobacter pylori infection, Arctic people, risk factors.
For citation: German S.V., Bobrovnitskiy I.P., Balakaeva A.V. Analysis of the prevalence of gastrointestinal malignancies. Russian Medical Inquiry. 2021;5(8):525–530 (in Russ.). DOI: 10.32364/2587-6821-2021-5-8-525-530.
About the authors:
Serafima V. German — Dr. Sc. (Med.), leading researcher of the Laboratory of Human Ecology and Public Health, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency; 10/1, Pogodinskaya str., Moscow, 119121, Russian Federation; ORCID iD 0000-0002-1628-199X.
Igor P. Bobrovnitskiy — Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Deputy Director General for Scientific Work, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency; 10/1, Pogodinskaya str., Moscow, 119121, Russian Federation; ORCID iD 0000-0002-1805-4010.
Alisa V. Balakaeva — C. Sc. (Biol.), senior researcher of the Laboratory of Human Ecology and Public Health, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency; 10/1, Pogodinskaya str., Moscow, 119121, Russian Federation; ORCID iD 0000-0003-4217-4300.
Contact information: Alisa V. Balakaeva, e-mail: ABalakaeva@cspmz.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 25.05.2021.
Revised 18.06.2021.
Accepted 13.07.2021.
2. Presidential Decree "On national strategic development objectives of the Russian Federation for the period up to 2024” (Electronic resource.) URL: http://kremlin.ru/acts/bank/43027 (access date: 12.12.2020) (in Russ.).
3. Malignant tumors in Russia in 2014 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Medical Radiological Research Centre — branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2016 (in Russ.).
4. Carmack A.M., Schade T.L., Sallison I. et al. Cancer in Alaska Native People: 1969–2013; The 45-Year Report. Alaska Native Tumor Registry, Alaska Native Epidemiology Center, Alaska Native Tribal Health Consortium, Anchorage, AK2015. (Electronic resource.) URL: http://anthctoday.org/epicenter/publications/Cancer45yearReport/45_Year_Report_FINAL_Online_Version.pdf (access date: 12.12.2020).
5. Kim J.Y., Bae B.N., Kang G. et al. Cytokine expression associated with Helicobacter pylori and Epstein-Barr virus infection in gastric carcinogenesis. APMIS. 2017;125(9):808–815. DOI: 10.1111/apm.12725.
6. Miernyk K.M., Bruden D., Rudolph K.M. et al. Presence of cagPAI genes and characterization of vacA s, i and m regions in Helicobacter pylori isolated from Alaskans and their association with clinical pathologies. J Med Microbiol. 2020;69(2):218–227. DOI: 10.1099/jmm.0.001123.
7. Nolen L.D., Vindigni S.M., Parsonnet J. Combating gastric cancer in Alaska native people: An expert and community symposium. Gastroenterology. 2020;158:1197–1201. DOI: 10.1053/j.gastro.2019.11.299.
8. Tan P., Yeoh K.G. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015;149(5):1153–1162. DOI: 10.1053/j.gastro.2015.05.059.
9. WHO. International Classification of Diseases for Oncology (ICD-O-3); 2018. (Electronic resource.) URL: http://codes.iarc.fr. (access date: 12.12.2020).
10. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492.
11. Kurilovich S.A., Reshetnikov O.V. Epidemiological studies in gastroenterology: long-term Siberian experience in the study of Helicobacter pylori associated diseases. Exp Wedge Gatroenterol. 2015;115(3):4–10 (in Russ.).
12. Bessonov P.P., Bessonova N.G., Krivoshapkin B.A. Issues of risk factors for atrophic gastritis in residents of Yakutia. Medicus.2019;26(2):22–28 (in Russ.).
13. Fagan-Garcia K., Geary J., Chang H.J. et al. Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities. BMC Public Health. 2019;19(1):730. DOI: 10.1186/s12889-019-7065-x.
14. Martinson H.A., Mallari D., Richter C. et al. Molecular Classification of Gastric Cancer among Alaska Native People. Cancers (Basel). 2020;12(1):198. DOI: 10.3390/cancers12010198.
15. Polivanova T.V. Issues of the formation and clinical course of diseases of the gastroduodenal zone in the population of the Far North. Siberian Medical Journal. 2012.108;1:10–13 (in Russ.).
16. Avakumova N.V., Chibieva N.G., Nikolaeva K.M. et al. Clinical and endoscopic characteristics of GERD, chronic gastritis and peptic ulcer disease in various ethnic groups of patients permanently living in the North. Bulletin of the North-Eastern Federal University. M.K. Ammosov. Series: Medical Sciences, 2017;4(9):8–11 (in Russ.).
17. Oh S., Kim N., Kwon J.W. et al. Effect of Helicobacter pylori Eradication and ABO Genotype on Gastric Cancer Development. Helicobacter. 2016;21(6):596–605. DOI: 10.1111/hel.12317.
18. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435–445. DOI: 10.1007/s10120-018-0876-0.
19. Seta T., Takahashi Y., Noguchi Y. et al. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. PLoS One. 2017;12(8):e0183321. DOI: 10.1371/journal.pone.0183321.
20. Hwang Y.J., Kim N., Lee H.S. et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication — a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–390. DOI: 10.1111/apt.14424.
21. Kim N. Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism. J Gastroenterol Hepatol. 2019;34(8):1287–1295. DOI: 10.1111/jgh.14646.
22. Del Moral-Hernández O., Castañón-Sánchez C.A., Reyes-Navarrete S. et al. Multiple infections by EBV, HCMV and Helicobacter pylori are highly frequent in patients with chronic gastritis and gastric cancer from Southwest Mexico: An observational study. Medicine (Baltimore). 2019;98(3):e14124. DOI: 10.1097/MD.0000000000014124.
23. Arnold M., Sierra M.S., Laversanne M. et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. DOI: 10.1136/gutjnl-2015-310912.
24. Odgaard M., Lohse N., Petersen A.J., Bæksgaard L. Oncological treatment and outcome of colorectal cancer in Greenland. Int J Circumpolar Health. 2018;77(1):1546069. DOI: 10.1080/22423982.2018.1546069.
25. Alberts S.R., Kelly J.J., Ashokkumar R., Lanier A.P. Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007. Int J Circumpolar Health. 2012;71:17521. DOI: 10.3402/IJCH.v71i0.17521.
26. Sleptsova S.S., Borisova N.N. The role of viral hepatitis in the mechanism of liver cancer formation in the indigenous people of the Far North. Viad Lek. 2015;68(4):464–468 (in Russ.).
27. Zalyalov B.A., Pimenov N.N., Komarova S.V. et al. Epidemiological features of hepatitis B and C in the Arctic. Epidemiology and infectious diseases. Topical issues. 2019;9(1):81–92 (in Russ.). DOI: 10.18565/epidem.2019.9.1.81-92.
28. Gounder P.P., Koch A., Provo G. et al. Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. Euro Surveill. 2018;23(40). DOI: 10.2807/1560-7917.ES.2018.23.40.1700408.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать